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Abstract
Background
Many patients treated for tuberculosis (TB) in low and middle income countries are treated
based on clinical suspicion without bacteriological confirmation. This is often due to lack of
rapid simple accurate diagnostics and low healthcare provider confidence in the predictive
value of current tests. We previously reported in an animal TB model that levels of host
markers rapidly change in response to treatment initiation.
Methods
We assessed the potential of host biomarker kinetics of TB patients during the first two
weeks of therapy to identify patients responding to treatment. Adult patients clinically diag-
nosed with and treated for TB, 29 in Nigeria and 24 in Nepal, were analyzed.
Results
Changes in concentrations of non-specific host biomarkers, particularly IP-10, in response
to the first week of anti-TB therapy were strongly associated with bacteriological confirma-
tion of TB. A decrease in IP-10 level of >300pg/ml between 0 and 7 days of treatment identi-
fied 75% of both smear-positive and smear-negative culture positive patients and correctly
excluded TB in all nine culture negative patients.
Conclusions
Monitoring of early IP-10 responses to treatment could form the basis of a simplified assay
and could help identify patients who were erroneously clinically diagnosed with TB or those
infected with drug resistant strains on inappropriate treatment. We believe this approach
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may be particularly appropriate for difficult to diagnose patients, e.g. smear-negative HIV-
positive, or those with extra-pulmonary TB, often treated without bacterial confirmation.
Introduction
Tuberculosis (TB) is a major public health problem worldwide, with an estimated 9.0 million
new cases each year [1]. Many patients with suspected TB initiate treatment without bacterio-
logical confirmation [2]. This is due to the lack of simple, rapid, and sensitive diagnostics com-
bined with poor healthcare provider confidence in the predictive value of current tests [3,4].
Sputum smear microscopy remains the most widely available diagnostic method for TB world-
wide despite the roll out of DNA amplification methods [1]. Smear microscopy however has
low sensitivity and does not provide information on drug susceptibility. A large number of sus-
pected TB patients are therefore treated empirically. This lack of confirmation can lead to
unnecessary anti-TB drug exposure in those who in fact have other conditions. Furthermore,
those infected with drug resistant strains often initially receive treatment with an ineffectual
first-line drug regimen.
Treatment monitoring is routinely performed by microscopically assessing sputum conver-
sion after at least 2 months of treatment. This has limited sensitivity and specificity [5] and is
only useful for a subset of (initially smear positive) patients. Therefore there is a desperate need
for new tools for determining the effectivity of treatment in all TB patients preferably in an
early stage of therapy. Serum concentrations of some cytokines correlate with TB. For example
increased concentrations of Interferon-gamma (IFNγ), Interferon gamma-induced protein 10
(IP-10), Interleukin-10 (IL-10), IL-6 and IL-12p40, and Tumor necrosis factor (TNFα) have
been reported at the time of diagnosis in adults with TB [6–8]. These levels generally return to
normal over the course of effective therapy [6,9], and patients who fail to respond maintain
high cytokine concentrations [10]. Cytokine kinetic responses have potential to monitor treat-
ment response [11].
Cytokine/chemokine concentrations change rapidly during the first week of therapy with
Rifampicin (RIF) and Isoniazid (INH) in a mouse model of TB [9]. If replicated in human TB
patients, these early changes could have potential as markers of treatment effectivity, and could
be useful for confirming an empirical diagnosis as well as for monitoring treatment response.
We therefore investigated the potential of cytokine kinetics in patients with suspected TB dur-
ing the first two weeks of therapy to confirm or refute a clinical diagnosis of TB and to identify,
relatively early, patients infected with drug resistantMycobacterium tuberculosis [11].
We also measured selected antibody kinetics upon treatment initiation. Although antibody
titers are known not to be useful for diagnosis of TB, we hypothesized that (free) serum anti-
body levels may increase upon bacterial killing and consequent stimulation by degradation
products, or decrease upon reduction of bacterial load.
Material and Methods
Patient recruitment
Fifty-four adults 18 years old with a least a two weeks history of cough and a presumptive
diagnosis of pulmonary TB were enrolled between May and June 2013. Of these, 16 and 9
patients respectively were enrolled at the German-Nepal Tuberculosis Project/Nepal Anti-TB
Association (GENETUP/NATA) and Tribhuvan University Teaching Hospital/Institute of
Medicine in Kathmandu, Nepal, and 29 patients were enrolled at the Wuse, Maitama, and
Host Marker Kinetics for TB
PLOSONE | DOI:10.1371/journal.pone.0129552 June 26, 2015 2 / 15
Competing Interests: The authors have declared
that no competing interests exist.
Nyanya district hospitals in Abuja, Nigeria. All patients gave written informed consent to par-
ticipate, and demographic and clinical data were collected using standard questionnaires. Sub-
jects treated for TB in the previous 2 years, those unable to attend follow up visits, and contacts
of known multi-drug-resistant (MDR) TB patients were excluded. One Nepalese patient with-
drew during the study and was excluded from the analysis.
All smear-positive and smear-negative patients clinically diagnosed as having TB were
enrolled consecutively by the hospital staff. Patients were retrospectively assigned to three cate-
gories: (a) smear positive culture positive; (b) smear negative culture positive, and (c) smear
negative culture negative.
The decision to treat the patients was based on clinical symptoms and smear microscopy,
however, GeneXpert became available in Nigeria and the results also provided to staff for clini-
cal management. Sputum specimens were cultured on solid media and in addition, were cul-
tured on BACTEC-MGIT 960 in Nigeria. Treatment outcomes at the end of therapy were
retrieved from the TB programme treatment cards 6 and 8 months after initiation of treatment.
Outcomes were reported following the World Health Organization (WHO) guidelines.
Both in Nepal and Nigeria, first line therapy consisted of 2 months of Rifampicin, Isoniazid,
Pyrazinamide and Ethambutol followed by 4 months rifampicin and isoniazid.
Ethics
Ethical approval was obtained from LSTM Research Ethics Committee (Reference number 273
[6-11-E]), the Institute of Medicine Tribhuvan University in Nepal, and the Federal Capital
Territory Medical Ethics Committee in Abuja, Nigeria (Reference number FHREC/2013/01/
24/05-07-13).
Serum collection
Blood samples were collected before starting anti-TB therapy (day 0) and on days 1, 3, 5, 7, and
14 after treatment initiation. In Nigeria an additional sample was collected at day 2.
Blood samples (2–5 ml) were collected in vacutainer tubes without anti-coagulants. After
30–60 minutes at room temperature, samples were centrifuged at 1,500 rpm for 15 minutes
and the resulting sera was stored at -80ºC. After transportation on dry-ice to The Netherlands,
samples were stored at -80ºC until analysis. Samples were blinded for all patient information
except study number and sampling day until after testing.
Cytokine assays
Samples were tested undiluted in duplicate according to the manufacturer’s guidelines using
bead-based multiplex assays HCYTOMAG-60K (Merck Millipore, Merck Chemicals B.V.,
Amsterdam, the Netherlands) for IP-10, IFNγ, monocyte chemotactic protein 1 (MCP-1), IL-
6, and TNFα, and the HCYP3MAG-63K assay (Merck Millipore) for Monokine induced by
gamma interferon (MIG). Plates were read using a Magpix machine (Luminex, Austin, Texas,
USA). Data analysis was performed using Milliplex analyst v5.1 software (Vigenetech, Carlisle,
Massachusetts, USA).
Antibody ELISAs
Recombinant HSP-16 (α-crystallin, Wageningen University and Research Center, Wagenin-
gen, The Netherlands) and ESAT-6 (BEI Resources, NIAID, NIH, USA) in PBS were coated at
4 μg/ml and 2 μg/ml respectively and incubated overnight at 4°C. Uncoated wells were included
as coating control. Plates were blocked with 10% newborn goat serum plus 0.1% Tween-20 in
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PBS (PBSNT) for 1h at 37°C. Samples were incubated in duplicate in PBSNT for 30 min at
37 oC at a 1/25 dilution. Samples with high titers were retested diluted up to 1/1000. A control
sample was included diluted 1/25, 1/50 and 1/100 in each plate. HRPO conjugate goat α human
IgG (H+L, Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) 1/20000 in
PBSNT was incubated for 1 h at 37°C. Detection was performed with TMB and the reaction
stopped after 20 min. Plates were read at 450 nm. Washing between all steps was performed with
PBS/0.05%Tween-20 (PBST).
Arbitrary units (AU) of antibodies against HSP-16 and ESAT-6 were calculated for each
sample by subtracting the Optic Density (OD) of the uncoated well from the antigen coated
well. To compare levels between different plates ODs were normalized to the 1/25 (set to 100
AU), 1/50 and 1/100 fold dilutions of the control sample.
PROTOLAM rapid tests
Semi-quantitative (negative, weakly positive, positive, or strongly positive) analysis of serum
antibodies was performed on samples from a representative selection of 31 culture positive and
negative patients. The lateral flow test (PROTOLAM, Lionex GmbH, Brunschweig, Germany)
has two lines, one detects LAM antibodies and one unspecified TB antibodies. Tests were per-
formed according to the manufacturer’s instructions.
Statistical analysis
Statistical testing was done using Stata 12.1. Two-sample Wilcoxon rank-sum (Mann-Whit-
ney) tests were used to test for differences between groups. Wilcoxon matched-pairs signed-
ranks test were performed for paired testing between time points. Rapid test data showed only
limited variability, the interpretation of which was quite subjective and was unsuitable for sta-
tistical testing.
Results
Patients
A total of 53 adult patients clinically diagnosed with and treated for TB were available for anal-
ysis (Table 1). Fifteen of 24 patients in Nepal were culture-positive (65%), eight culture-nega-
tive, and one contaminated. Eleven of the 15 culture-positive patients were smear-positive and
all culture-negative patients were smear-negative (Table 1). Twenty-eight of 29 (97%) patients
in Nigeria were culture and or GeneXpert positive. Of these, 20 were smear-positive and eight
smear-negative (Table 1). One patient in Nigeria was smear-, culture-, and GeneXpert-nega-
tive. GeneXpert RIF resistance was detected in three Nigerian patients and their isolates under-
went drug susceptibility testing (DST). DST identified one patient infected with an MDR TB
strain also resistant to Ethambutol and Streptomycin, one with a strain resistant to RIF and
streptomycin, and one with a fully susceptible strain. One further isolate underwent DST
(mono-resistant to streptomycin) on the basis of clinical suspicion of drug resistance. HIV sta-
tus was available for all patients in Nigeria and 20 of 24 in Nepal. Fifteen (52%) patients in
Nigeria and one (4%) in Nepal were HIV-positive. Seven patients in Nigeria were on anti-retro-
viral therapy (ART) prior to TB diagnosis, three started ART at the same time as anti-TB medi-
cation, for six HIV positive patients this data was not available.
Serum Cytokines levels at diagnosis and follow up
The median serum level of IP-10 at diagnosis (day 0) was elevated in culture/GeneXpert posi-
tive patients compared to culture/GeneXpert negative patients (p<0.001; Fig 1). Among
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patients with positive culture/GeneXpert results, IP-10 levels were significantly higher in HIV-
positive than in HIV-negative patients (p<0.01). There was no association between smear pos-
itivity and IP-10 level on enrolment (p = 0.484; Fig 1).
The median IP-10 concentration of culture positive patients decreased during the course of
therapy regardless of smear microscopy and HIV status (p<0.0001 overall, p<0.01 for each
subgroup at day 7), as shown in Fig 2. For all culture positive sub-groups (HIV+/-, Smear +/-)
IP-10 concentrations were significantly lower at days 5, 7, and 14 than on enrolment (Fig 2, S1
Fig). In contrast, culture-negative patients had similar IP-10 concentrations at the time of
enrolment and at day 7 (p = 0.086; Fig 2). Although numbers of patients in each group are
small, IP-10 responses of patients on established or simultaneously initiated ART had similar
patterns and changes were likely related to anti-TB therapy not ART.
We performed ROC analyses and produced ROC curves demonstrating the ability of cyto-
kine shifts between day 0 and day 7 of treatment to identify patients receiving appropriate
treatment. For IP-10, the area under the ROC curve was 0.88 [95% CI 0.79–0.97], p<0.001
(Panel A in S2 Fig). Based on the ROC curve for IP-10 response, we set a threshold of 300 pg/ml
decrease between enrolment (day 0) and day 7 of treatment to differentiate between patients
receiving appropriate of inappropriate treatment. This threshold of at least a decrease of
300 pg/ml at day 7confirmed appropriate treatment in 33 (75%) of 44 bacteriologically-
Table 1. Patient characteristics.
Nepal Nigeria
Number 24a 29
Median age [range] 27 [19–69] 32 [18–50]
Male sex (%) 19 (79.2) 21 (72.4)
Duration of symptoms in weeks [range] 3.5 [1–52] 8 [2–40]
Duration of cough (weeks) 2.5 [0–52] 8 [2–40]
HIV positive (%) 1 (4.2), 4 NA 15 (51.7)
Smear positive (%) 12 (50) 20 (69.0)
Positive solid culture (%) 15 (62.5), 1 NAd 24 (82.8), 3 NA
Positive liquid culture (%) NA 24 (82.8), 3 NA
GeneXpert MTB (%) NA 28 (96.6)
Combined Culture and GeneXpert resultc 15 (62.5), 1 NAd 28 (96.6)
GeneXpert RIF resistance (%) NA 3 (10.3)
DST results (of 4 patients tested) NA 1 RIF+STR resistance
1 MDR+STR+EMB resistance
1 STR resistance
1 Pansusceptible
Treatment outcomes NA 14 curedb
8 treatment completed
5 transferred out
2 defaulted treatment
None died
NA: Not available (for cultures this includes contamination).
a Excludes 1 withdrawn patient see Methods.
b Reported result for both RIF resistant cases.
c Number of samples positive by either or both Culture/GeneXpert.
d The patient with NA culture was Smear positive and was included in the Culture/GeneXpert positive
group in the analyses.
doi:10.1371/journal.pone.0129552.t001
Host Marker Kinetics for TB
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confirmed patients and detected no response in all nine (100%) culture-negative patients
(Table 2). Twenty-four (75%) of 32 smear-positive (Fig 2A and 2B) and nine (75%) of 12 smear-
negative culture-positive patients (Fig 2C and 2D) had a decrease in IP-10 between day 0 and day
7>300 pg/ml. Nine (90%) of 10 smear-positive cases co-infected with HIV had a decrease in IP-
10 levels>300 pg/ml by day 7 (Fig 2A), while one patient had an increase of 1240 pg/ml. This lat-
ter patient was infected with MDR TB (Fig 2A, Dashed line) and had consistently elevated IP-10
concentrations until day 14 of the follow up (Panel A in S1 Fig).
IFNγ, IL-6, and TNFα concentrations showed similar patterns as IP-10, although in a lower
concentration range (Fig 3, Fig 4, Fig 5, S2 Fig, S3 Fig, S4 Fig, S5 Fig). TNFα decreased in cul-
ture/GeneXpert positive patients (p<0.001 for the overall difference between days 0 and day 7,
p-values between 0.02 and 0.5 for individual smear positive and negative, HIV positive and
negative subgroups), and no significant change was seen in culture/GeneXpert negative
patients (p>0.05). IFNγ and IL-6 levels in culture/GeneXpert positive patients decreased
between days 0 and 7 (overall both p<0.0001) and changes were weakly significant in culture/
GeneXpert negative patients (p = 0.05 and 0.03, respectively). In ROC analysis of these cyto-
kine shifts to identify patients receiving appropriate treatment, the areas under the curve
Fig 1. Baseline IP-10 concentrations by HIV status, Smear status, and TB culture/GeneXpert result. Box plots showmedians and ranges for patients,
grouped based on HIV, Smear, and culture/GeneXpert result (**p<0.01).
doi:10.1371/journal.pone.0129552.g001
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(AUC) were 0.78 [95% CI 0.63–0.94], p>0.01 for IFNγ, 0.80 [95% CI 0.65–0.95], p<0.01 for
IL-6, and 0.64 [95% CI 0.46 to 0.82], p>0.05 for TNFα, respectively (Panels B-D in S2 Fig).
MIG serum levels in culture/GeneXpert positive patients decreased between days 0 and 5 to 7
(p<0.001; Fig 6, S6 Fig). However median concentrations had returned to enrolment values by
day 14. This transient decrease in MIG was not observed in culture-negative patients (p>0.05).
In ROC analysis performed as described above, AUC for the day 0-day7 change in MIG levels
was 0.81 [95% CI 0.69 to 0.94], p<0.01 (Panel E in S2 Fig).
No changes in MCP-1 concentrations could be consistently correlated to culture/GeneXpert
result (p>0.05; Fig 7, S7 Fig), nor to appropriate treatment (AUC of ROC curve day0-day7:
0.67 [95% CI 0.47 to 0.87], p>0.05, Panel F in S2 Fig).
Fig 2. Serum IP-10 concentrations at day 0 and 7 of therapy. Each set of 2 connected points represent data from a single patient from Nigeria (blue) or
Nepal (red). Panel A: IP-10 concentrations of HIV-positive, Smear (Sm) positive, and culture/Xpert (Cult) positive patients. The MDR-TB patient is shown with
a dashed line. One smear-positive patient had missing culture (Open symbols). Panel B-D: IP-10 concentrations of HIV- Sm+ (B), HIV+ Sm- (C), and HIV-
Sm- (D) culture/GeneXpert positive patients. E: Concentrations from Sm-Cult- patients, of which 4 had missing HIV result (open square symbols) and all
others were HIV- (round symbols). IP-10 levels in culture/GeneXpert positives were significantly different between day 0 and day 7 (p<0.0001). For culture/
GeneXpert negatives p>0.05 between day 0 and day 7.
doi:10.1371/journal.pone.0129552.g002
Table 2. Distribution of samples with serum IP-10 decreasing >300 pg/ml between day 0 and day 7.
Culture/GeneXpert+ Smear HIV N Samples (%) with IP-10 decrease of >300pg/ml
Yes Smear+ HIV+ 10 9 (90)*
HIV- 22 15(68)
Total smear+ 32 24(75)
Smear- HIV+ 6 5(83)
HIV- 6 4 (67)
Total smear- 12 9(75)
Total 44 33 (75)
No Smear+ HIV+ 0 NA
HIV- 0 NA
Total smear+ 0 NA
Smear- Unknown 5 0(0)
HIV- 4 0(0)
Total smear- 9 0(0)
Total 9 0 (0)
* the not responding patient was conﬁrmed MDR.
doi:10.1371/journal.pone.0129552.t002
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Serum Antibody concentrations
There was a high variation in antibody levels against HSP-16 and ESAT-6 on enrolment (>103
fold). Antibody titers remained remarkably stable within the two week follow up (Fig 8), with
slightly lower HSP antibody concentrations at day 14 in culture-negative patients (p<0.039).
The absolute change was small (median change 5 AU and 15 AU between day 0 and 14 in cul-
ture/GeneXpert positive and culture-negative patients respectively).
Thirty one patients were tested by lateral flow assays for serum antibodies against LAM and
other TB antigens. Of those 13 (59%) of 22 culture/GeneXpert positive and two (22%) of nine
culture negative patients showed a detectable band in the PROTOLAM assay at day 0
(Table 3). In three patients a change in positivity grade was identified between day 0 and day
14; two went from positive to weakly positive and one from weakly positive to negative between
days 0 and 14. The TB-ST test gave detectable bands in four (18%) of 22 culture/GeneXpert-
positive samples.
Fig 3. Serum IFNγ levels of TB patients at day 0 and day 7 of therapy. See legend Fig 2 for details on the panels and labels. For culture/GeneXpert
positive patients p<0.001 between day 0 and day 7. For culture/GeneXpert negative patients p<0.05 between day 0 and 7.
doi:10.1371/journal.pone.0129552.g003
Fig 4. Serum IL-6 levels of TB patients at day 0 and day 7 of therapy. See legend Fig 2 for details on the panels and labels. Between day 0 and day 7, for
culture/GeneXpert positive patients p<0.001; between day 0 and day 7, for culture/GeneXpert negative patients, p<0.05.
doi:10.1371/journal.pone.0129552.g004
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Discussion
The diagnosis of smear-negative TB is still a clinical challenge despite the development of new
in vitro assays in the last decades. Nearly half of the patients treated for TB in low and middle
income countries are treated based on clinical suspicion without bacteriological confirmation
[1]. Thus, many of these patients may not have TB and are unnecessarily exposed to prolonged
treatment with anti-TB drugs and remain untreated for their underlying conditions. Further-
more, newly diagnosed TB patients are in general presumed to be infected with drug-sensitive
strains. Patients infected with unidentified drug resistant strains typically undergo several
months of ineffective therapy before monitoring results reveal the prescribed treatment as
inappropriate [12]. Therefore, there is an urgent need to develop new diagnostic tools that
could confirm a clinical diagnosis of TB and identify patients potentially infected with drug
resistant strains.
We described the serum kinetics of IP-10, IFNy, IL-6, MIG, TNFα, and MCP-1 before and
during the first two weeks of treatment in patients with presumptive TB to explore whether
cytokine responses have the potential to confirm a clinical diagnosis in patients without
Fig 5. Serum TNFα levels of TB patients at day 0 and day 7 of therapy. See legend Fig 2 for details on the panels and labels. P<0.001 between day 0 and
day 7; No significant differences between day 0 and day 7 for culture/GeneXpert negative patients.
doi:10.1371/journal.pone.0129552.g005
Fig 6. SerumMIG levels of TB patients at day 0 and day 7 of therapy. See legend Fig 2 for details on the panels and labels. P<0.001 between day 0 and
day 7 for culture/GeneXpert positive patients No significant differences between day 0 and day 7 for culture/GeneXpert negative patients.
doi:10.1371/journal.pone.0129552.g006
Host Marker Kinetics for TB
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bacteriological confirmation and be used as early surrogate markers of treatment response to
identify drug-resistant TB.
Most patients in the study with bacteriologically confirmed TB had increased baseline IP-10
concentrations. IP-10 serum levels have been previously found to be elevated in patients with
TB [10,13]. However, IP-10 concentrations may also be elevated in unrelated diseases,[14]
impairing specificity [15].
The early responses of the cytokines to anti-TB treatment correlated well with TB infection
in a mouse model [9]. Here IP-10 serum concentrations decreased after 7 days of therapy
among the majority of bacteriologically confirmed cases and a decrease of>300 pg/ml between
baseline and day 7 values was observed in 75% of both smear-positive and smear-negative
patients, suggesting that the pattern is independent of the number of bacilli in sputum.
Fig 7. SerumMCP-1 levels of TB patients at day 0 and day 7 of therapy. See legend Fig 2 for details on the panels and labels. There are no significant
differences between day 0 and day 7 for either culture/GeneXpert positive patients or culture/GeneXpert negative patients.
doi:10.1371/journal.pone.0129552.g007
Fig 8. Serum antibody levels at day 0 and day 14 of therapy. Arbitrary Units (AU) of serum levels of antibodies against HSP-16 (A-C), and ESAT-6 (D-F)
from a subset of TB patients. Data shown for smear positive culture/GeneXpert positive (A, D), smear negative culture/GeneXpert positive (B, E) and smear
negative culture/GeneXpert negative patients (C, F). * indicates p = 0.039 between day 0 and day 14. In all other groups no significant differences were
found between day 0 and 14.
doi:10.1371/journal.pone.0129552.g008
Host Marker Kinetics for TB
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HIV-TB co-infected patients are more difficult to diagnose and thus are more likely to
receive empirical and potentially inappropriate TB treatment [3]. Patients co-infected with
HIV had significantly higher baseline IP-10 levels than HIV-negative patients, which contrasts
with previous studies reporting no statistical difference between the groups [13,16]. Despite the
observed difference at baseline in our patients, TB therapy resulted in IP-10 reductions among
both HIV-positive and HIV-negative patients with bacteriologically confirmed TB. It must be
noted that none of the culture negatives were confirmed to be HIV coinfected thus an effect of
HIV infection on the response of culture negative TB patients could not be excluded. Increased
serum levels of IP-10 have been reported to return to baseline during and after TB therapy
[10,13,16–18] and monitoring IP-10 after starting treatment or post treatment may be clini-
cally informative [19] to predict cure or detect relapse [20]. In our study we demonstrated that
changes in IP-10 levels in response to therapy can be detected at much earlier time points, irre-
spective of smear or HIV status. IP-10 concentrations were higher than all other cytokines
except MIG and are therefore easier to measure than the other markers. We produced ROC
curves demonstrating the ability of cytokine shifts between day 0 and day 7 of treatment to
identify patients receiving appropriate treatment. Based on these analyses we were able to set
criteria that classified 75% of the culture positive (including 75% of the smear-negative culture
positive) patients as responding based on a threshold of 300pg/ml decrease in IP-10. All nine
culture negative patients were identified as being on inappropriate treatment after seven days
of treatment. It must also be noted that at least one of the non responding culture/GeneXpert
positives was infected with an MDR TB strains based on subsequent DST testing. Our results
thus demonstrate that IP-10 response between 0–7 days of treatment can be used for identify-
ing patients on inappropriate treatment, who may then be prioritized for further characteriza-
tion of infection and resistance profile by rapid molecular methods. Nonetheless this is a
preliminary study and accurately defined criteria for response or lack of response should be
established based on ROC curve analyses on larger studies including individuals with latent
infection and uninfected suspects.
Although the responses of IFNγ, IL-6, and MIG after one week of treatment followed the
same trend as IP-10, the accuracies of IFNγ, IL-6, and MIG kinetics for classification of TB
patients as being on appropriate /inappropriate treatment were lower than for IP-10. There
was also more fluctuation between time points. Changes in MCP-1 and TNFα levels with
Table 3. Rapid test results at days 0 and 14 of treatment.
PROTOLAM TB-ST
Total N
tested
Total
positives
day 0
Total
positives
day 14
N of patients with
changed grade day
0-day 14
Total
positives day
0
Total
positives day
14
N of patients with
changed grade day
0-day14*
Culture/
GeneXpert+
total 22 13 12 3* 4 4 0
sm+ 16 10 9 3*; 1pt w to neg 3 3 0
2pt p to w
sm- 6 3 3 0 1 1 0
Culture/
GeneXpert-
sm- 9 2 2 0 0 0 0
Bands were graded as strongly positive, positive (p), weakly positive (w), or negative (neg). No changes in band intensity between day 0 and 14 were
identiﬁed for the TB-ST, and only 3 in the PROTOLAM test.
* indicates numbers of patients (pt) with a difference in band intensity between day 0 to day 14.
doi:10.1371/journal.pone.0129552.t003
Host Marker Kinetics for TB
PLOSONE | DOI:10.1371/journal.pone.0129552 June 26, 2015 11 / 15
therapy were too small (Area under the ROC curves of 0.67 and 0.64 respectively) and incon-
sistent to have potential as markers of early treatment response.
A limitation of our study is that we did not control or monitor other conditions that may
increase IP-10 levels. However, many of these conditions would not be expected to respond to
TB therapy. We also did not look at any possible link between the magnitude of IP-10
responses early in treatment (or later) and treatment failure/relapse, this would be interesting
to investigate this in larger studies. Full DST was only available for four patients, and there may
have been cases with mono resistance that were not identified. Different drugs target different
bacterial subpopulations [21] and early bactericidal activity (EBA) is higher for INH than for
RIF [22]. To our knowledge there is no data on the cytokine responses of patients exposed to
single drugs, but it is possible that the drug with the strongest EBA (INH) is responsible for the
majority of the effect observed. The effects of individual drugs and the corresponding effect of
different resistance phenotypes on the early cytokine response remain to be investigated.
The antibodies levels, as measured by ELISA and lateral flow assays, did not change during
the initial 14 days of therapy. Increases in antibody titers during the early phase of therapy
have been reported by some [23] but not all authors [24] and this seems to depend on the anti-
gen [25]. Our data confirms that the utility of measuring anti-TB antibodies kinetics is limited.
The diagnosis and management of TB suspects is constrained by the intrinsic limitations in
accuracy and timeliness of results with current, predominantly sputum reliant, diagnostic
methods. Furthermore, in low and middle income countries, cost and infrastructure limit the
availability of newer assays such as GeneXpert despite its concessionary pricing. The utility of
sputum PCR is also limited for certain groups, such as patients with extra-pulmonary TB,
patients unable to expectorate sputum, and in paediatric TB. A blood based approach that
assesses the IP-10 response to TB treatment has the potential to supplement current strategies
especially for these difficult to diagnose groups.
In conclusion, serum concentration changes of relatively non-specific host biomarkers, par-
ticularly IP-10, in response to the first week of anti-TB therapy were strongly associated with
subsequent bacteriological confirmation of TB and provided early evidence of treatment
response. Monitoring IP-10 response to treatment may help identify patients who are errone-
ously clinically diagnosed with TB or those infected with drug resistant strains on inappropri-
ate treatment. Near patient testing of these markers using simple platforms before and one
week after initiation of therapy is feasible. This approach is promising and especially useful for
difficult to diagnose patients, such as smear-negative HIV-positive patients, those unable to
expectorate sputum, extra-pulmonary TB, and pediatric TB patients, often treated without bac-
terial confirmation.
Supporting Information
S1 Fig. Relative serum IP-10 levels in Nigerian (blue) and Nepalese (red) TB patients at day
0 to day 14 of therapy. Levels shown are relative to day 0 levels (day 0 subtracted), negative
values thus indicating a decrease and positive values indicating an increase compared to day 0.
Panel A: Relative cytokine concentrations of HIV-positive, Smear (Sm) positive, and culture/
Xpert (Cult) positive patients. The MDR-TB patient is shown with a dashed line. One smear-
positive patient had missing culture (Open symbols). Panel B-D: Relative cytokine concentra-
tions of HIV- Sm+ (B), HIV+ Sm- (C), and HIV- Sm- (D) culture/GeneXpert positive patients.
E: Relative cytokine concentrations from Sm-Cult- patients, of which 4 had missing HIV result
(open square symbols) and all others were HIV- (round symbols).
(EPS)
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S2 Fig. Receiver operating characteristic (ROC) curves showing the ability of cytokine
shifts between day 0 and day 7 to identify patients receiving appropriate treatment. Patients
receiving appropriate treatment were defined as those with confirmed (culture/GeneXpert pos-
itive)TB without evidence of MDR. Patients receiving inappropriate treatment were defined as
those not infected with strains susceptible to the prescribed treatment, i.e. the culture/GeneX-
pert negative patients + MDR patients. Complete ROC statistics are presented in the Results
section.  p<0.05,  p<0.01,  p<0.001.
(EPS)
S3 Fig. Relative serum IFNγ levels in Nigerian (blue) and Nepalese (red) TB patients at day
0 to day 14 of therapy. See legend S1 Fig for details on the panels and labels.
(EPS)
S4 Fig. Relative serum IL-6 levels in Nigerian (blue) and Nepalese (red) TB patients at day
0 to day 14 of therapy. See legend S1 Fig for details on the panels and labels.
(EPS)
S5 Fig. Relative serum TNFα levels in Nigerian (blue) and Nepalese (red) TB patients at
day 0 to day 14 of therapy. See legend S1 Fig for details on the panels and labels.
(EPS)
S6 Fig. Relative serumMIG levels in Nigerian (blue) and Nepalese (red) TB patients at day
0 to day 14 of therapy. See legend S1 Fig for details on the panels and labels.
(EPS)
S7 Fig. Relative serumMCP-1 levels in Nigerian (blue) and Nepalese (red) TB patients at
day 0 to day 14 of therapy. See legend S1 Fig for details on the panels and labels.
(EPS)
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